Health News

FDA Approves Gattex to Treat Short Bowel Syndrome
The US Food and Drug Administration today approved Gattex (teduglutide) to treat adults with short bowel syndrome (SBS) who need additional nutrition from intravenous feeding (parenteral nutrition).
Energy Drinks May Give a Killer Buzz
While energy drinks may give you a lift, consuming too many can be unhealthy. Caffeine levels are currently not listed on these drinks, but recent FDA investigations may change that.
Mixed Report Card on Teen Substance Use
Teens may be drinking and smoking less – but they are smoking out more. Cigarette smoking and alcohol use are at their lowest levels among teens while pot use has climbed.
Seeing Through the Medical Radiation Risk Story
Imagine if you had a cancer that needed to be treated right away. The doctor orders CT scans. Would the fact that radiation exposure from the tests increases your lifetime cancer risks keep you from having the scans?
Growing Up – and Growing Obese – with TV
More than 70 percent of children and teenagers have TVs in their bedrooms. But just having a TV in their rooms puts them at higher risk for becoming fat.
The Secret to Growing Old Gracefully
Just about everyone wants the secret to life. But they might settle for the secret to aging gracefully. One important key to successfully aging appear to be… growing older.
Why'd the Man Cross the Road?
Stop, look and listen: it applies to everyone and not just kids and chickens crossing the road. Guys should be extra careful as well.
Diabetes Connected to Broken Bones
Diabetes has been linked to so many complications they can seem hard to count. Now, it looks like risk of broken bones can be added to the list.
Overcoming Cancer Fatigue
The exhaustion that comes with cancer may feel like an unmovable brick wall, but it doesn’t have to. There are strategic guidelines to help patients battle fatigue successfully.
Merck Drug Tredaptive Did Not Achieve Primary Endpoint
Merck, known outside the United States and Canada as MSD , today announced that the HPS2-THRIVE (Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events) study of TREDAPTIVE™ (extended-release niacin/ laropiprant ) did not meet its primary endpoint.
<< first885886887888889890891892893last >>

REFINE